Source: innovationintextiles
Dr Kevin Nelson, TissueGen’s founder and CSO, will be presenting on the latest advancements in extrusion technology, which are enabling the next generation of drug delivery, at BIOMEDevice Boston, this week.
Dr Nelson will discuss how the evolution of the medical device industry has brought drug delivery to the forefront of the market. More than ever before, drug delivery coupled with a medical device is improving patient care. The emergence of new extrusion methods that occur at or below body temperature are enabling drug-loading of a wider range of pharmaceutical and biological agents than ever before possible for use in biodegradable implantable devices for localised drug delivery within the body.
The incorporation of these drug-loaded fibres into new or existing medical devices may result in faster healing, improved patient compliance and lower negative outcomes at lower cost for applications including spinal cord repair, nerve regeneration, tumour remediation and more.
BIOMEDevice Boston, which takes place from 18-19 April at the Boston Convention & Exhibition Center, Boston, MA, connects visitors with more than 4,500 engineers and executives and more than 450 leading suppliers across New England's thriving medical technology industry.
TissueGen, a developer of Elute fibre, enables controlled sustained delivery of sensitive pharmaceuticals and biologics from biodegradable fibres for advanced drug delivery, nerve regeneration and tissue engineering.
TissueGen works with leading pharmaceutical, therapeutic and medical device companies to develop fibre and textile medical devices for use in drug delivery applications, such as small diameter vascular grafts and stents, tissue and nerve regeneration, orthopaedic devices and sutures.
